Federation des caisses Desjardins du Quebec’s Context Therapeutics CNTX Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio CNTX Stock Details CNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-400	Closed	-$802	–	2594
2024 Q2	$802	Hold	400	–	–	﹤0.01%	2209
2024 Q1	$552	Hold	400	–	–	﹤0.01%	2235
2023 Q4	$452	Hold	400	–	–	﹤0.01%	2206
2023 Q3	$604	Hold	400	–	–	﹤0.01%	2198
2023 Q2	$640	Hold	400	–	–	﹤0.01%	2171
2023 Q1	$225	Hold	400	–	–	﹤0.01%	2255
2022 Q4	$261	Buy	+400	New	+$431	﹤0.01%	2389

Other funds holding CNTX

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's CNTX Position: Q3 2024 in Review

Federation des caisses Desjardins du Quebec sold out of Context Therapeutics (CNTX) in Q3 2024, closing a stake of 400 shares — an estimated $802 sold.

Federation des caisses Desjardins du Quebec first reported a position in CNTX in Q4 2022 and held it in 7 quarters. The position peaked at $802 in Q2 2024. 42 funds tracked by Wall St. Rank hold CNTX as of Q3 2024.

Federation des caisses Desjardins du Quebec reported no remaining Context Therapeutics position as of Q3 2024 after selling out during the quarter.
Federation des caisses Desjardins du Quebec sold 400 Context Therapeutics shares in Q3 2024, an estimated $802.
Federation des caisses Desjardins du Quebec first reported a position in Context Therapeutics in Q4 2022 and held it in 7 quarters.
Federation des caisses Desjardins du Quebec's Context Therapeutics position peaked at $802 in Q2 2024.
42 funds tracked by Wall St. Rank held Context Therapeutics as of Q3 2024.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q3 2024, filed 13 Nov 2024.